Abstract

Abbreviations ADCs Adenocarcinomas ALDH1A1 Aldehyde dehydrogenase 1 family member A1 ALK Anaplastic lymphoma kinase CSC Cancer stem cell CCL20 Chemokine (C-C motif) ligand 20 CCR6 chemokine receptor 6 DGE Differential gene expression DTP Drug-tolerant persister EGFR Epidermal growth factor receptor EML4 Echinoderm microtubule-associated protein-like 4 ELISA Enzyme-linked immunosorbent assay FOS Fos Proto-Oncogene NANOG Homeobox protein NANOG ICAM-1 Intercellular adhesion molecule 1 IL-17 Interleukin-17 LCOs Lung cancer organoids MUC5AC Mucin-5AC NSCLC Non-small cell lung carcinoma POU5F1 POU Class 5 Homeobox 1 PROM1 Prominin 1 PTGS2 Prostaglandin-endoperoxide synthase 2 RORɣ Retinoid-related orphan receptor-γ S100A9 S100 calcium-binding protein A9 scRNA-seq Single-cell RNA sequencing TCGA-LUAD The Cancer Genome Atlas Lung Adenocarcinoma Th17 T helper-17 lymphocytes TKIs Tyrosine kinase inhibitors TNF Tumor necrosis factor UMI Unique molecular index UMAP Uniform Manifold Approximation and Projection Dear Editor, Non-small cell lung carcinoma (NSCLC) accounts for more than 85% of all lung cancers [ 1]. Differential gene expression (DGE) analysis of drug-resistant and drug-sensitive TS485T-O LCOs revealed that the interleukin-17 (IL-17) signaling pathway was enriched in both crizotinib-resistant and alectinib-resistant tumor organoids ( Supplementary Figure S2C-D). [...]we found that the actin cytoskeleton regulatory pathway was downregulated in both FA34-O crizotinib-resistant and alectinib-resistant tumor organoids ( Supplementary Figure S2E-F). Abbreviations: Anterior gradient 2 (AGR2); Chemokine (C-C motif) ligand 20 (CCL20); BPI fold containing family A, member 1 (BPIFA1); Cancer susceptibility candidate 1 (CASC1); Cell division cycle 20B (CDC20B); Carcinoembryonic antigen cell adhesion molecule 6 (CEACAM6); Cilia and flagella associated protein 126 (CFAP126); Coiled-Coil Domain Containing 170 (CCDC170); Coronin 2A (CORO2A); C-X-C motif chemokine ligand 8 (CXCL8); Dynein axonemal assembly factor 1 (DNAAF1); Dynein axonemal heavy chain 7 (DNAH7); EF-hand domain family member B (EFHB); Ferritin heavy chain 1 (FTH1); GINS complex subunit (GINS1); Hypoxia-inducible factors (HIF); Leucine Rich Repeat Containing 46 (LRRC46); Matrix metallopeptidase 1 (MMP1); Meiosis specific nuclear structural 1 (MNS1); Nicotinamide phosphoribosyltransferase (NAMPT); Nucleotide oligomerization domain (NOD); Myocardial infarction associated transcript (MIAT); Paternally Expressed 10 (PEG10); PIH1 domain containing 3 (PIH1D3); Primary cilia formation (PIFO); Prosaposin (PSAP); Ras-proximate-1 (RAP1); Radial spoke head component 1 (RSPH1); Regulator of cell cycle (RGCC); Rho family GTPase 1 (RND1); Rhophilin associated tail protein 1 like (ROPN1L); Ribosomal Protein L10 (RPL10); Insulin like growth factor binding protein 5 (IGFBP5); Intercellular adhesion molecule 1 (ICAM-1); Interleukin-17 (IL-17); S100 Calcium Binding Protein A9 (S100A9); Trefoil factor 1 (TFF-1); Tetraspanin 1 (TSPAN1); Threonine tyrosine kinase (TTK); T helper-17 lymphocytes (Th17); WAP four-disulfide core domain protein 2 (WFDC2) CCL20, mainly produced by mucosal lymphoid tissues, is a chemokine that directs lymphocyte migration toward epithelial cells.

Details

Title
Single-cell transcriptomic analysis uncovers intratumoral heterogeneity and drug-tolerant persister in ALK-rearranged lung adenocarcinoma
Author
Hoi-Hin Kwok 1   VIAFID ORCID Logo  ; Li, Huiyu 2 ; Yang, Jiashuang 1 ; Deng, Junyang 1 ; Nerissa Chui-Mei Lee 1 ; Au, Timmy Wing-Kuk 3 ; Alva Ko-Yung Sit 3 ; Hsin, Michael Kuan-Yew 3 ; Ma, Stephanie Kwai-Yee 4 ; Cheung, Lydia Wai-Ting 4 ; Girard, Luc 2 ; Fujimoto, Junya 5 ; Wistuba, Ignacio Ivan 5 ; Gao, Boning 2 ; John Dorrance Minna 2 ; David Chi-Leung Lam 1   VIAFID ORCID Logo 

 Department of Medicine, Li Ka Shing Faculty of Medicine, University of Hong Kong, Hong Kong SAR, P. R. China 
 Nancy B. and Jake L. Hamon Center for Therapeutic Oncology Research, University of Texas Southwestern Medical Center, Dallas, Texas, USA 
 Cardiothoracic Surgical Department, Queen Mary Hospital, Hong Kong SAR, P. R. China 
 School of Biomedical Sciences, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong SAR, P. R. China 
 Department of Translational Molecular Pathology, Division of Pathology/Lab Medicine, University of Texas MD Anderson Cancer Center, Houston, Texas, USA 
Pages
951-955
Section
LETTERS TO THE EDITOR
Publication year
2023
Publication date
Aug 2023
Publisher
John Wiley & Sons, Inc.
e-ISSN
2523-3548
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2844966605
Copyright
© 2023. This work is published under http://creativecommons.org/licenses/by-nc-nd/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.